MedTrace Logo

A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting

NCT01926912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 371

Last updated 2015-08-24

No results posted yet for this study

Summary

The purpose of this study to evaluate safety, tolerability, treatment outcomes, appropriate use and pattern of paliperidone palmitate usage in participants with schizophrenia in the hospital setting.

Conditions

Interventions

DRUG

No intervention

This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.

Sponsors & Collaborators

  • Janssen-Cilag International NV

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag International NV Clinical Trial · Janssen-Cilag International NV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Belgium
  • Bulgaria
  • Denmark
  • Germany
  • Greece
  • Israel
  • Kazakhstan
  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01926912 on ClinicalTrials.gov